Answers are grounded in this paper and cite their sources.
Demonstrates severe anaphylactoid reactions to cisatracurium even at precurarizing doses, highlighting an estimated incidence of 1 in 10,000 despite presumed low histamine release.
On its introduction into clinical anesthesia, cisatracurium was expected to be practically devoid of histamine releasing potential (1) and to be a less potent trigger of allergic reaction than other muscle relaxants (2). However, eventually four reports of anaphylactic reactions after cisatracurium administration were published (3–6). We report another six incidents that, for the first time, include two severe anaphylactoid reactions after precurarising doses of a muscle relaxant in current clinical use. Two cases occurred in the University Hospital of Cologne and four others occurred in neighboring facilities. Five of these cases were subject to a previous brief communication (7). All patients underwent intradermal allergy testing 3 mo after the incident. The tests included all substances used with premedication and induction of anesthesia, namely midazolam, flunitrazepam, fentanyl, thiopental, remifentanil, propofol, prilocaine, cisatracurium as well as pancuronium, alcuronium, and succinylcholine. Intradermal testing started with 1:1000 solutions and, in case of no response, continued with 1:100. The results were compared with those of three healthy volunteers. To assess the incidence of anaphylactoid reactions from cisatracurium, we estimated the underlying total patient population treated with cisatracurium in the participating hospitals. Results Patient data and histories are summarized in Table 1. The doses of cisatracurium ranged from 12 μg/kg used for precurarization in patient number 5 to 167 μg/kg in patient number 1. Anaphylactoid reactions occurred within 2–20 min after induction of anesthesia. Three patients developed wheezing with increased airway resistance that was associated with arterial hypoxemia in patient number 2. Arterial hypotension was seen in five patients, tachycardia in three, and bradycardia with ventricular conduction block in one. In patient number 3, urticaria and flush were the only anaphylactoid manifestations. All patients survived. On skin testing, all patients reacted to the cisatracurium solutions 1:100 or 1:1000. With 1:1000 a cutaneous reaction was only observed in patient number 3 and patient number 6. However, in addition, patient number 6 suffered intense conjunctival itching and rhinitis, whereas the remaining four (numbers 1, 2, 4, 5) required the 1:100 concentration to elicit cutaneous symptoms. No systemic reactions were observed. Three healthy control subjects did not respond to any test solution. No patient responded to any drug other than cisatracurium and atracurium.Table 1: Patient Data and SymptomsSince its introduction into the four source hospitals, cisatracurium may have been administered to some 60,000 patients. Thus, as a rough estimate, the incidence of anaphylactoid reactions in response to cisatracurium might be in the order of 1:10,000. Discussion Mast cell degranulation with histamine release is the common end point of both the immunologically (immunoglobulin [Ig] E-) mediated Type I anaphylactic and the pharmacologically mediated anaphylactoid reactions (8). As a more general term, “anaphylactoid” may also refer to both mechanisms because the diagnosis is clinical and presently there is no chance to discriminate between the two types of reaction. The trigger substance is usually identified by skin testing that only indicates the release of histamine regardless of the underlying mechanism. Serum tryptase activity may help to confirm the diagnosis of anaphylaxis. Additional allergen-specific IgE antibody testing would be required to prove an IgE-mediated anaphylactic response (e.g., radioallergosorbent test [RAST], Pharmacia CAP System; Pharmacia, Uppsala, Sweden) (9) that is unavailable for cisatracurium. Four anaphylactoid incidents after cisatracurium administration were previously reported (3–6). A 70-yr-old female developed generalized flush, increased airway resistance, arterial hypoxemia, arterial hypotension, and bradycardia with ST-depression. Cisatracurium 8 mg was part of the induction of anesthesia. Because prick tests with succinylcholine, propofol, and rocuronium were negative as opposed to a positive prick test with cisatracurium, the triggering drug was clearly identified. With reference to a marginally increased plasma concentration of prostaglandin D2, the reaction was considered IgE-mediated (3,10). In a subsequent report (4) on a 29-yr-old female, a 10 mg dose of cisatracurium was followed by sinus tachycardia of 145 bpm and a Spo2 decrease from 96% to 67%. The arterial blood pressure was not measurable and cardiopulmonary resuscitation was required. Positive prick testing identified cisatracurium as the trigger. In view of a positive prick test for cisatracurium 1:100 rather than 1:1000, the authors assumed an IgE-mediated reaction as the most likely mechanism. In a third report (5) a 6-yr-old boy suffered life-threatening bronchospasm. No intracutaneous tests were performed but specific IgE was found in an “allergy possible” range for both thiopental and cisatracurium. As to a recent fourth report (6), a 10-yr old boy, after cisatracurium administration, developed generalized erythema and wheezing. However, besides cisatracurium, intradermal testing was positive also for sufentanil and hydroxyethyl starch (which were part of the procedure). In our six patients, cisatracurium was clearly identified as the trigger substance by comprehensive skin testing. However, with respect to the limited reliability of indirect methods such as serum tryptase or prostaglandin D2 determination, we did not attempt any immunological classification. In contrast to the identification of the triggering substance, this is clinically less relevant, as the triggering substance should not be applied to such a patient. The overall incidence of muscle relaxant–induced anaphylactoid reactions has been estimated in the order of 1:7500 (11). Clearly, our data are not suitable for comparative statistics. Nevertheless, when attempting a cautious estimate of the incidence of cisatracurium-induced anaphylactoid reactions, our result of 1:10,000 would appear rather similar or probably somewhat more favorable. However, an overall clinical appreciation of the anaphylactoid potential should not just concentrate on the numeric incidence of untoward reactions but also consider their severity and the underlying doses of the trigger substance. Therefore our two incidents after only precurarizing doses merit particular attention. Only one case has been reported in the literature where shortly after a 1-mg priming dose of vecuronium and 0.1 mg fentanyl, a 41-yr old female exhibited a “uniform macular rash and difficult breathing”(12). The authors suggested vecuronium as the trigger of this “histaminoid reaction” although no allergy tests were performed. In conclusion, although cisatracurium may be a less potent histamine liberator than atracurium (1), its anaphylactoid potential may not be proportionally less. The authors thank Dr. S. van der Schyff for preparing the English manuscript and Dr. J. Scholpp, Medical Advisor, GlaxoWellcome, Germany, for critical review of the text.
No takes yet. Share an insight, caveat, or question.
Krombach et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: